Satsuma Pharmaceuticals (NSDQ:STSA) has announced that it has enrolled the first patient in its SUMMIT Phase 3 efficacy trial of STS101, a drug-device product that is a potential acute treatment of migraine. STS101 is a nasal powder containing dihydroergotamine (DHE), an analgesic already available to treat migraines and cluster headaches. In fact, migraine patients have […]
Nominations open for the Leonard Award celebrating 100 years of insulin
Eli Lilly and Company (NYSE:LLY) is looking for nominations for its inaugural Leonard Award, which highlights advances in diabetes management. The company will select five winners and donate $100,00 to the non-profit Life for a Child, which provides medicines and supplies to children and youth with type 1 diabetes in developing countries. Lilly is launching the […]
Walmart teams up with Novo Nordisk to launch private-brand analog insulin
Walmart (NYSE:WMT) is launching what it describes as the first private label analog insulin. The company estimates the insulin products will save customers between 58% and 70% of the cost of branded insulin. Novo Nordisk (NYSE:NVO) will manufacture the analog insulin, which is a type of lab-grown insulin genetically engineered to optimize glucose control. The […]
San Diego company aiming to target glioblastoma with nanotechnology-based approach
Glioblastoma, which kills roughly Americans each year, remains challenging to treat. The emerging biopharmaceutical company Global Cancer Technology (GCT; San Diego) is developing a novel x-ray activated modality for drug delivery to treat glioblastoma. GCT has a licensing agreement with the University of California, San Diego (UCSD) for a drug delivery platform that unites a […]
Bionaut Labs receives orphan drug designation for its lead therapeutic
FDA has granted orphan drug designation to the drug-device startup Bionaut Labs (Los Angeles) for the company’s lead therapeutic program, BNL-101, for the local treatment of malignant gliomas. BNL-101 is a drug-device combination that brings together remote-controllable microscale robotics and the chemotherapy agent doxorubicin. In March, the startup received $20 million in funding from Khosla Ventures. […]
FDA classifies Novo Nordisk insulin pen recalls as Class I
In May, Novo Nordisk announced that it voluntarily recalled 1,468 product samples related to its Levemir, Tresiba, Fiasp, Novolog and Xultophy insulin lines. The products were held at sub-freezing temperatures, prompting the FDA to recently classify the recalls as Class I. FDA uses the Class I designation for situations where there is “a reasonable probability” […]
Researchers reverse diabetes in mice using nanoscale device
Scientists at Washington University (St. Louis) and Cornell University (Ithaca, N.Y.) successfully implanted insulin-secreting cells in mice with type 1 diabetes. The cells proved capable of reversing chemically-induced diabetes for up to 200 days after implantation, according to a recent article in Science Translational Medicine. To do so, they used a nanofiber-integrated cell encapsulation (NICE) device […]
SEC lawsuit accuses RenovaCare of securities fraud
The biotech RenovaCare (OTCMKTS: RCAR) announced that it has received a civil complaint from the Securities and Exchange Commission (SEC). The SEC accuses Harmel S. Rayat, a controlling shareholder and chair of RenovaCare, of orchestrating a secret promotional campaign to elevate the company’s stock price. The agency claimed that Rayat and RenovaCare worked with the financial publishing […]
How EyePoint Pharmaceuticals is developing sustained-release drug delivery for eye diseases
Dedicated to developing treatments for serious eye disorders, EyePoint Pharmaceuticals’ (NASDAQ: EYPT) pipeline includes a proprietary technology for sustained intraocular drug delivery known as Durasert. The technology supports the use of EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration, which can cause severe vision problems. To learn more about […]
Insulet shares down after Q1 miss
Insulet (NSDQ:PODD) stock is down today — a day after the wearable insulin delivery system developer posted break-even Q1 results that were lower than analysts’ expectations. The company, however, yesterday evening raised the low end of its revenue guidance range to 16–20%. The range was previously 15–20%. The Acton, Mass.-based company a net loss of […]
